Leerink Swann Analysts Cut Earnings Estimates for AC Immune SA (ACIU)

AC Immune SA (NASDAQ:ACIU) – Stock analysts at Leerink Swann reduced their FY2017 earnings estimates for AC Immune SA in a research note issued on Monday. Leerink Swann analyst P. Matteis now forecasts that the company will earn ($0.62) per share for the year, down from their previous estimate of ($0.55). Leerink Swann also issued estimates for AC Immune SA’s Q4 2017 earnings at ($0.09) EPS and FY2019 earnings at ($1.23) EPS.

ILLEGAL ACTIVITY WARNING: “Leerink Swann Analysts Cut Earnings Estimates for AC Immune SA (ACIU)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/11/16/leerink-swann-analysts-cut-earnings-estimates-for-ac-immune-sa-aciu.html.

A number of other equities research analysts have also issued reports on ACIU. Credit Suisse Group set a $18.00 target price on shares of AC Immune SA and gave the company a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research lowered shares of AC Immune SA from a “hold” rating to a “sell” rating in a research note on Thursday, July 20th.

Shares of AC Immune SA (ACIU) opened at $10.75 on Thursday. AC Immune SA has a 12 month low of $6.03 and a 12 month high of $17.47.

Several large investors have recently made changes to their positions in the stock. Cohen Lawrence B bought a new stake in shares of AC Immune SA during the 2nd quarter valued at about $297,000. Goldman Sachs Group Inc. bought a new stake in shares of AC Immune SA during the 2nd quarter valued at about $127,000. Janney Montgomery Scott LLC bought a new stake in shares of AC Immune SA during the 3rd quarter valued at about $134,000. Finally, Wells Fargo & Company MN bought a new stake in shares of AC Immune SA during the 3rd quarter valued at about $111,000. 18.02% of the stock is owned by institutional investors and hedge funds.

AC Immune SA Company Profile

AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Earnings History and Estimates for AC Immune  SA (NASDAQ:ACIU)

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply